A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.

被引：0
|
作者：
Shaikh, Saba
Zang, Yan
Hanmer, Janel
Wang, Hong
Lin, Yan
Davar, Diwakar
Zarour, Hassane M.
Kirkwood, John M.
Najjar, Yana G.
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[3] UPMC Hillman Canc Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21506
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
    Shaikh, Saba S.
    Zang, Yan
    Hanmer, Janel
    Wang, Hong
    Lin, Yan
    Davar, Diwakar
    Zarour, Hassane M.
    Kirkwood, John M.
    Najjar, Yana G.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [3] Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.
    Gonzalez-Cao, Maria
    de las Casas, Clara Mayo
    Oramas, Juana
    Berciano-Guerrero, Miguel-Angel
    De la Cruz, Luis
    Cerezuela-Fuentes, Pablo
    Arance, Ana Maria
    Munoz-Couselo, Eva
    Espinosa, Enrique
    Puertolas, Teresa
    Beveridge, Robert Diaz
    Ochenduszko, Sebastian
    Silva, Maria Jose Villanueva
    Basterretxea, Laura
    Bellido, Lorena
    Rodriguez-Abreu, Delvys
    Drozdowskyj, Ana
    Vila, Miguel Angel Molina
    Lopez-Martin, Jose Antonio
    Berrocal, Alfonso
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] The combination of vemurafenib and cobimetinib in advanced melanoma
    Spain, Lavinia
    Goode, Emily
    McGovern, Yevette
    Joshi, Kroopa
    Larkin, James
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (11): : 1105 - 1111
  • [5] Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial
    Grimaldi, Antonio M.
    Simeone, Ester
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (03) : 209 - 215
  • [6] Cobimetinib and Vemurafenib Convincing test combination in Patients with advanced Melanoma
    Satzger, Ulla
    ONCOLOGY RESEARCH AND TREATMENT, 2015, 38 (09) : 475 - 475
  • [7] A phase I trial of panobinostat with ipilimumab in advanced melanoma.
    Khushalani, Nikhil I.
    Markowitz, Joseph
    Eroglu, Zeynep
    Giuroiu, Iulia
    Ladanova, Viktoriya
    Reiersen, Pamela
    Rich, Jeani
    Thapa, Ram
    Schell, Michael J.
    Sotomayor, Eduardo M.
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] A phase I clinical trial investigating the telomerase vaccine UV1 in combination with pembrolizumab in patients with advanced melanoma.
    Zakharia, Yousef
    O'Day, Steven
    Rasch, Wenche
    Milhem, Mohammed M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
    Ryan J. Sullivan
    Omid Hamid
    Rene Gonzalez
    Jeffrey R. Infante
    Manish R. Patel
    F. Stephen Hodi
    Karl D. Lewis
    Hussein A. Tawbi
    Genevive Hernandez
    Matthew J. Wongchenko
    YiMeng Chang
    Louise Roberts
    Marcus Ballinger
    Yibing Yan
    Edward Cha
    Patrick Hwu
    Nature Medicine, 2019, 25 : 929 - 935
  • [10] Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
    Sullivan, Ryan J.
    Hamid, Omid
    Gonzalez, Rene
    Infante, Jeffrey R.
    Patel, Manish R.
    Hodi, F. Stephen
    Lewis, Karl D.
    Tawbi, Hussein A.
    Hernandez, Genevive
    Wongchenko, Matthew J.
    Chang, YiMeng
    Roberts, Louise
    Ballinger, Marcus
    Yan, Yibing
    Cha, Edward
    Hwu, Patrick
    NATURE MEDICINE, 2019, 25 (06) : 929 - +
12345